Biopharmaceutical contract development and manufacturing organization (CDMO) NorthX Biologics, is pleased to announce the appointment of Magnus Gustafsson as Chief Commercial Officer (CCO).
Magnus brings an exceptional wealth of experience from global roles across the pharma, biotech and CDMO industries. His proven expertise in building and leading commercial teams will be vital as NorthX expands its reach, particularly in new markets like North America.
Magnus holds an MSc in biotechnology from the Royal Institute of Technology, a PhD in Medical Biochemistry and Biophysics from Karolinska Institute and an MBA from Stockholm Business School.
Janet Hoogstraate, CEO NorthX Biologics comments: “I am delighted to welcome Magnus to the team as we continue our growth journey. His impressive credentials and experience will be invaluable to both the leadership team and the business.”
Magnus Gustafsson adds: “NorthX Biologics offers an impressive range of services, from microbial and mammalian recombinant proteins to viral products, mRNA, plasmids, cell therapy, and exosomes. The company’s reputation as a trusted partner, with satisfied clients and expert staff, makes it an exciting time to join. I look forward to working with the team to support our clients in delivering life-changing therapies to patients worldwide.”
Media inquiries
Please contact Janet Hoogstraate, CEO, janet.hoogstraate@nxbio.com
